1型人类免疫缺陷病毒通过干热凝血因子浓缩物传播。输血安全研究小组。

Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group.

作者信息

Dietrich S L, Mosley J W, Lusher J M, Hilgartner M W, Operskalski E A, Habel L, Aledort L M, Gjerset G F, Koerper M A, Lewis B H

机构信息

University of Southern California, Los Angeles.

出版信息

Vox Sang. 1990;59(3):129-35. doi: 10.1111/j.1423-0410.1990.tb00846.x.

DOI:10.1111/j.1423-0410.1990.tb00846.x

PMID:2124751

Abstract

The Transfusion Safety Study monitored susceptible persons for human immunodeficiency virus type 1 (HIV-1) infections transmitted by plasma products and blood components. Through December, 1988, 6 subjects without antibody to HIV-1 (anti-HIV-1) became seropositive after receiving dry-heated factor VIII concentrate. The preparations implicated in 3 cases were derived entirely from anti-HIV-1-screened donors. In all instances, HIV-1 infection could be explained by concentrates heated at 60 degrees C for 24-30 h. Limiting consideration to concentrates and components administered after study entry showed that 4 of the seroconversions occurred among 122 subjects given 10 million units of factor VIII concentrates. No seroconversions occurred among 84 subjects given 5 million units of factor IX concentrates, or 83 who received components from over 26,000 unpaid donations. Serologic surveillance of anti-HIV-1-negative subjects provides important information, and should be routine in the management of persons receiving clotting factor concentrates.

摘要

输血安全研究对易感染人群进行监测，以了解由血浆制品和血液成分传播的1型人类免疫缺陷病毒（HIV-1）感染情况。截至1988年12月，6名无HIV-1抗体（抗HIV-1）的受试者在接受干热灭活的凝血因子VIII浓缩剂后血清学转为阳性。3例相关制剂完全来自经抗HIV-1筛查的献血者。在所有病例中，HIV-1感染都可归因于在60摄氏度下加热24至30小时的浓缩剂。仅考虑研究开始后使用的浓缩剂和成分，在接受1000万单位凝血因子VIII浓缩剂的122名受试者中，有4例发生了血清转化。在接受500万单位凝血因子IX浓缩剂的84名受试者中，以及在接受来自超过26000例无偿献血成分的83名受试者中，均未发生血清转化。对抗HIV-1阴性受试者的血清学监测可提供重要信息，在接受凝血因子浓缩剂治疗的患者管理中应作为常规措施。